Literature DB >> 20448659

Functional imaging of renal cell carcinoma.

Nathan Lawrentschuk1, Ian D Davis, Damien M Bolton, Andrew M Scott.   

Abstract

The incidence of early and advanced-stage renal cell carcinoma (RCC) is increasing. Methods of diagnosing, staging and evaluating tumor burden that are more accurate and reliable than the currently available options are needed in order to identify RCC at a stage at which it is curable and to accurately determine the response to treatment. Functional imaging, particularly with combined PET-CT, might improve accuracy of detection and provide essential information that has been unavailable to date. This approach is against a background in which targeted therapies for metastatic RCC have entered clinical practice in the past few years, further highlighting the importance of accurate imaging for patient selection and for monitoring response to treatment. We outline the current clinical status of functional imaging in RCC using PET-CT, which allows simultaneous capture and co-registration of functional and anatomical data. New radiotracers and approaches-including radiolabeled monoclonal antibodies and imaging of tumor hypoxia-are touched on, and areas of future research discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20448659     DOI: 10.1038/nrurol.2010.40

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  83 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan.

Authors:  E Seto; G M Segall; M K Terris
Journal:  Urology       Date:  2000-02       Impact factor: 2.649

3.  Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

Authors:  Michael Atkins; Meredith Regan; David McDermott; James Mier; Eric Stanbridge; Amanda Youmans; Philip Febbo; Melissa Upton; Mirna Lechpammer; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

4.  131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study.

Authors:  A H Brouwers; U Dorr; O Lang; O C Boerman; W J G Oyen; M G Steffens; E Oosterwijk; H G Mergenthaler; H Bihl; F H M Corstens
Journal:  Nucl Med Commun       Date:  2002-03       Impact factor: 1.690

5.  [Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results].

Authors:  R Bachor; F Kocher; F Gropengiesser; S N Reske; R E Hautmann
Journal:  Urologe A       Date:  1995-03       Impact factor: 0.639

6.  In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations.

Authors:  M G Steffens; E Oosterwijk; M H Kranenborg; J M Manders; F M Debruyne; F H Corstens; O C Boerman
Journal:  J Nucl Med       Date:  1999-05       Impact factor: 10.057

Review 7.  Will targeted therapy hold its promise? An evidence-based review.

Authors:  David Murdoch; Jason Sager
Journal:  Curr Opin Oncol       Date:  2008-01       Impact factor: 3.645

Review 8.  Metastatic renal cell carcinoma: recent advances in the targeted therapy era.

Authors:  Giuseppe Di Lorenzo; Riccardo Autorino; Cora N Sternberg
Journal:  Eur Urol       Date:  2009-09-08       Impact factor: 20.096

9.  In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.

Authors:  Wouter B Nagengast; Elisabeth G de Vries; Geke A Hospers; Nanno H Mulder; Johan R de Jong; Harry Hollema; Adrienne H Brouwers; Guus A van Dongen; Lars R Perk; Marjolijn N Lub-de Hooge
Journal:  J Nucl Med       Date:  2007-07-13       Impact factor: 10.057

10.  Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.

Authors:  David Lyrdal; Marianne Boijsen; Madis Suurküla; Sven Lundstam; Ulrika Stierner
Journal:  Nucl Med Commun       Date:  2009-07       Impact factor: 1.690

View more
  8 in total

Review 1.  Imaging renal cell carcinoma with ultrasonography, CT and MRI.

Authors:  Michael J Leveridge; Peter J Bostrom; George Koulouris; Antonio Finelli; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2010-05-18       Impact factor: 14.432

2.  Assessment of cell proliferation in renal cell carcinoma using dual-phase 18F-fluorodeoxyglucose PET/CT.

Authors:  Rei Onishi; Masanori Noguchi; Hayato Kaida; Fukuko Moriya; Katsuaki Chikui; Seiji Kurata; Akihiko Kawahara; Masayoshi Kage; Masatoshi Ishibashi; Kei Matsuoka
Journal:  Oncol Lett       Date:  2015-06-11       Impact factor: 2.967

3.  Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications.

Authors:  Jehonathan H Pinthus; Kaitlyn F Whelan; Daniel Gallino; Jian-Ping Lu; Nathan Rothschild
Journal:  Can Urol Assoc J       Date:  2011-08       Impact factor: 1.862

Review 4.  Molecular imaging of urogenital diseases.

Authors:  Steve Y Cho; Zsolt Szabo
Journal:  Semin Nucl Med       Date:  2014-03       Impact factor: 4.446

Review 5.  Nuclear imaging of renal tumours: a step towards improved risk stratification.

Authors:  Michael A Gorin; Steven P Rowe; Mohamad E Allaf
Journal:  Nat Rev Urol       Date:  2015-06-09       Impact factor: 14.432

6.  Pharmacokinetics, metabolism, biodistribution, radiation dosimetry, and toxicology of (18)F-fluoroacetate ((18)F-FACE) in non-human primates.

Authors:  Ryuichi Nishii; William Tong; Richard Wendt; Suren Soghomonyan; Uday Mukhopadhyay; Julius Balatoni; Osama Mawlawi; Luc Bidaut; Peggy Tinkey; Agatha Borne; Mian Alauddin; Carlos Gonzalez-Lepera; Bijun Yang; Juri G Gelovani
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

Review 7.  Active surveillance of small renal masses.

Authors:  Marc C Smaldone; Anthony T Corcoran; Robert G Uzzo
Journal:  Nat Rev Urol       Date:  2013-04-09       Impact factor: 14.432

8.  Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer.

Authors:  Marc C Smaldone; David Yt Chen; Jian Q Yu; Elizabeth R Plimack
Journal:  Biologics       Date:  2012-11-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.